Program
roluperidone
Also written as “MIN-101”, “Roluperidone 64 mg” and “Roluperidone”.
Its studies are mostly in Schizophrenia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Minerva Neurosciences | 61 open or running | phase 3since Dec 29, 2017 | Sep 3, 2014 | Dec 2027phase 3 · NCT07565428 |
| Cyrenaic Pharmaceuticals | 10 open or running | phase 2since Mar 11, 2009 | Mar 11, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 11, 2009First study: phase 2 study in SchizophreniaNew to Cyrenaic PharmaceuticalsCyrenaic Pharmaceuticals · NCT00861796 · 100 enrolled · France
- Sep 3, 2014Minerva Neurosciences's first study: phase 1 study in SchizophreniaNew to Minerva NeurosciencesMinerva Neurosciences · NCT02232529 · 32 enrolled · United Kingdom
- Jan 10, 2017Phase 1 study in Healthy SubjectsMinerva Neurosciences · NCT03038646 · 14 enrolled · Ireland
- Feb 23, 2017Phase 1 study in Healthy SubjectsMinerva Neurosciences · NCT03072056 · 23 enrolled · Ireland
- Dec 29, 2017Phase 3 study in Negative Symptoms of SchizophreniaMinerva Neurosciences · NCT03397134 · 515 enrolled · United States, Bulgaria, Poland and more
- Oct 13, 2023Phase 1 study in Negative Symptoms in SchizophreniaMinerva Neurosciences · NCT06107803 · 17 enrolled · United States
- Apr 21, 2026Phase 3 study in Negative Symptoms of SchizophreniaMinerva Neurosciences · NCT07565428 · 380 planned · United States
Ahead
- Dec 2027Primary completion: phase 3 study in Negative Symptoms of SchizophreniaMinerva Neurosciences · NCT07565428
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07565428Negative Symptoms of Schizophrenia · United States | 3 | Recruiting | Minerva Neurosciences | Dec 2027 | 380 |
| NCT06107803Negative Symptoms in Schizophrenia · United States | 1 | Completed | Minerva Neurosciences | Jan 12, 2024 | 17 |
| NCT03397134Negative Symptoms of Schizophrenia · United States, Bulgaria, Poland and more | 3 | Completed | Minerva Neurosciences | May 26, 2020 | 515 |
| NCT03072056Healthy Subjects · Ireland | 1 | Completed | Minerva Neurosciences | Jul 7, 2017 | 23 |
| NCT03038646Healthy Subjects · Ireland | 1 | Completed | Minerva Neurosciences | Apr 20, 2017 | 14 |
| NCT02232529Schizophrenia · United Kingdom | 1 | Completed | Minerva Neurosciences | Feb 2015 | 32 |
| NCT00861796Schizophrenia · France | 2 | Completed | Cyrenaic Pharmaceuticals | May 2010 | 100 |
How it is read
Names in the registry
- “MIN-101”, 3 entries
- “Roluperidone 64 mg”, 2 entries
- “Roluperidone”, 1 entry
- “Roluperidone 32 mg”, 1 entry
- “CYR-101”, 1 entry
Conditions, from the studies’ own filings
- Schizophrenia, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.